Piperine alleviates osteoclast formation through the p38/c‐Fos/NFATc1 signaling axis
- 12 November 2015
- journal article
- research article
- Published by Wiley in BioFactors
- Vol. 41 (6) , 403-413
Abstract
: Increased bone fracture is one of the health risk factors in patients with bone loss related disorders such as osteoporosis and breast cancer metastasis to bone. Over activity of osteoclasts leads to uncoupling of bone remodeling favoring bone loss over bone formation. Receptor activator of nuclear factor‐κβ ligand (RANKL) triggers the differentiation pathway leading to multinucleated osteoclast formation. Modulation of RANKL or its downstream signaling pathways involved in osteoclast formation is of significant interest in the development of anti‐resorptive agents. In this study, the effects of piperine, an alkaloid present in Piper nigrum L. on osteoclast formation was investigated. Piperine inhibited tartrate‐resistant acid phosphatase‐positive multinucleated osteoclast formation in murine RAW264.7 macrophages and human CD14+ monocytes induced by RANKL and breast cancer cells. Piperine attenuated the p38‐mitogen activated protein kinase pathway activation, while the extracellular‐signal‐regulated kinase, c‐Jun N‐terminal kinase, or NF‐κβ pathways downstream of RANKL remained unaffected. Concomitantly, expression of c‐Fos and nuclear factor of activated T‐cells, cytoplasmic 1 (NFATc1), the key transcription factors involved in osteoclastogenesis were remarkably inhibited by piperine. Furthermore, piperine disrupted the actin ring structure and bone resorption, a characteristic hallmark of osteoclasts. Collectively, these results suggested that piperine inhibited osteoclast differentiation by suppressing the p38/NFATc1/c‐Fos signaling axis. © 2015 BioFactors, 41(6):403–413, 2015Keywords
This publication has 53 references indexed in Scilit:
- Effect of Age on Regulation of Human Osteoclast DifferentiationJournal of Cellular Biochemistry, 2014
- Bone metastases: Causes, consequences and therapeutic opportunitiesEuropean Journal of Cancer Supplements, 2013
- Mesenchymal Stem Cells in the Aging and Osteoporotic PopulationCritical Reviews™ in Eukaryotic Gene Expression, 2011
- RANK/RANKL: Regulators of Immune Responses and Bone PhysiologyAnnals of the New York Academy of Sciences, 2008
- Osteoclast lineage and functionArchives of Biochemistry and Biophysics, 2008
- Biology of RANK, RANKL, and osteoprotegerinArthritis Research & Therapy, 2007
- Mechanism of osteoclast mediated bone resorption—rationale for the design of new therapeuticsAdvanced Drug Delivery Reviews, 2005
- Expression of membrane-bound and soluble receptor activator of NF-κB ligand (RANKL) in human T cellsImmunology Letters, 2004
- Tumour cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastasesJournal of Clinical Pathology, 2002
- Minireview: Transcriptional Control of Osteoblast DifferentiationEndocrinology, 2001